BCYRN1 and Alzheimer disease: The researchers also found that the degree of cognitive impairment was correlated with the levels of lncRNA BC200 and NEAT1 in individuals with Alzheimer's disease; in concluding their study, they noted that plasma levels of BC200 and NEAT1 may be helpful to be used as biomarkers for identifying and tracking the progression of late-onset AD [62].